UCB SA (UCB.BR) Stock Price, Forecast & Analysis
Europe • Euronext Brussels • EBR:UCB • BE0003739530
UCB.BR Key Statistics, Chart & Performance
The current stock price of UCB.BR is 256.2 EUR. In the past month the price increased by 6.04%. In the past year, price increased by 34.43%.
UCB.BR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 87.25% of all stocks.
UCB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. Both the profitability and the financial health of UCB.BR get a neutral evaluation. Nothing too spectacular is happening here.
UCB.BR Financial Highlights
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.45% | ||
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| Debt/Equity | 0.29 |
UCB.BR Forecast & Estimates
25 analysts have analysed UCB.BR and the average price target is 263.84 EUR. This implies a price increase of 2.98% is expected in the next year compared to the current price of 256.2.
For the next year, analysts expect an EPS growth of 60.25% and a revenue growth 25.37% for UCB.BR
UCB.BR Ownership
About UCB.BR
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
UCB SA / UCB.BR FAQ
What does UCB do?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Can you provide the latest stock price for UCB SA?
The current stock price of UCB.BR is 256.2 EUR. The price increased by 1.26% in the last trading session.
What is the dividend status of UCB SA?
UCB SA (UCB.BR) has a dividend yield of 0.38%. The yearly dividend amount is currently 1.36.
What is the ChartMill rating of UCB SA stock?
UCB.BR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for UCB stock?
The PE ratio for UCB SA (UCB.BR) is 39.91. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 256.2 EUR.
What is UCB SA worth?
UCB SA (UCB.BR) has a market capitalization of 49.83B EUR. This makes UCB.BR a Large Cap stock.